Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.

"Declaration of personal interests: DK has received speaker honoraria from Norgine. JH has received speaker honoraria from Takeda and has served as a consultant for Janssen‐Cilag. JM has served as a speaker, consultant or advisory board member for AbbVie, Bayer, Bristol‐Myers Squibb, Hospira, Janssen‐Cilag, Merck Sharp & Dohme, Pfizer, Sandoz, Takeda and Union Chimique Belge, and has received grant support from AbbVie, Calpro AS, Fresenius Kabi, Pfizer, SVAR Life Science and Takeda (not for this study). Declaration of funding interests: This work was made possible through the financial support from the Healthcare Region of Southern Sweden, and by grants to researchers in the public health care from the Swedish government (ALFSKANE‐539811) to Jan Marsal."

"Funding information"